Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ELU001 |
| Synonyms | |
| Therapy Description |
ELU001 is a nanoparticle C'Dot drug conjugate that contains the topoisomerase-1 inhibitor exatecan and folic acid, which delivers the drug to FRalpha-expressing cells, potentially resulting in anti-tumor activity in FRalpha-overexpressing cancers (Cancer Res July 1 2021 (81) (13 Supplement) 305). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ELU001 | FA-CDC | ELU001 is a nanoparticle C'Dot drug conjugate that contains the topoisomerase-1 inhibitor exatecan and folic acid, which delivers the drug to FRalpha-expressing cells, potentially resulting in anti-tumor activity in FRalpha-overexpressing cancers (Cancer Res July 1 2021 (81) (13 Supplement) 305). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05001282 | Phase Ib/II | ELU001 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) | Terminated | USA | 0 |